We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$116M
AUM Growth
+$21M
Cap. Flow
+$284M
Cap. Flow %
244.1%
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122

Top Buys

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$4.59M
2
BIIB icon
Biogen
BIIB
+$3.56M
3
CALM icon
Cal-Maine
CALM
+$2.79M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.48M
5
AAPL icon
Apple
AAPL
+$2.33M

Sector Composition

Rank Sector Weight
1 Healthcare 41.4%
2 Technology 6.27%
3 Consumer Staples 4.14%
4 Consumer Discretionary 2.26%
5 Materials 1.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HRTX icon
376
PUT
Heron Therapeutics
HRTX
$89.1M
-2,500
Closed -$7K
IBB icon
377
PUT
iShares Biotechnology ETF
IBB
$9.23B
-120,000
Closed -$19K
IBM icon
378
PUT
IBM
IBM
$200B
-7,845
Closed -$1K
INCY icon
379
PUT
Incyte
INCY
$23.4B
-23,000
Closed -$52K
KO icon
380
PUT
Coca-Cola
KO
$351B
-25,000
Closed -$5K
LUMN icon
381
Lumen
LUMN
$6.47B
-3,300
Closed -$96.1K
META icon
382
CALL
Meta Platforms (Facebook)
META
$1.64T
-5,000
Closed -$25K
META icon
383
PUT
Meta Platforms (Facebook)
META
$1.64T
-20,000
Closed -$41K
MNKD icon
384
CALL
MannKind Corp
MNKD
$1.25B
-24,000
Closed -$71K
MNST icon
385
Monster Beverage
MNST
$95.4B
-1,578
Closed -$38.1K
NBIX icon
386
CALL
Neurocrine Biosciences
NBIX
$17.2B
-17,500
Closed -$20K
NBIX icon
387
PUT
Neurocrine Biosciences
NBIX
$17.2B
-35,000
Closed -$24K
NSC icon
388
CALL
Norfolk Southern
NSC
$76.4B
-71,800
Closed -$288K
NSC icon
389
PUT
Norfolk Southern
NSC
$76.4B
-12,500
Closed -$36K
PEP icon
390
PUT
PepsiCo
PEP
$187B
-22,500
Closed -$80K
PFE icon
391
CALL
Pfizer
PFE
$143B
-79,050
Closed -$8K
PFE icon
392
Pfizer
PFE
$143B
-22,857
Closed -$643K
PFE icon
393
PUT
Pfizer
PFE
$143B
-79,050
Closed -$72K
PGEN icon
394
PUT
Precigen
PGEN
$1.76B
-70,630
Closed -$37K
PSA icon
395
CALL
Public Storage
PSA
$55.8B
-20,000
Closed -$103K
PTCT icon
396
PTC Therapeutics
PTCT
$6.52B
-22,954
Closed -$168K
RDWR icon
397
Radware
RDWR
$1.27B
-25,000
Closed -$296K
RDWR icon
398
PUT
Radware
RDWR
$1.27B
-25,000
Closed -$156K
RMBS icon
399
CALL
Rambus
RMBS
$11B
-5,100
Closed -$5K
RTX icon
400
CALL
RTX Corp
RTX
$261B
-105,033
Closed -$277K

Similar funds

FT Options's Q2 2016 Portfolio in Review

As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.

On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.

  • FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
  • FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
  • FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
  • FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
  • FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
  • FT Options opened 171 new positions and closed 122 in Q2 2016.
  • FT Options's portfolio value rose 22% quarter-over-quarter to $116M.

Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.